For the roughly 6 million Americans living with atrial fibrillation, catheter ablation has become an increasingly common ...

J&J has reported interim 12-month results from the VARIPURE study, assessing the effectiveness and safety of its Varipulse PFA platform in first-time users.

Boston Scientific shared the results during a late-breaking presentation at this year’s EHRA congress in Paris, France.

Pulse Biosciences recently advanced its nPulse Cardiac Catheter Ablation System by enrolling the first patients in its pivotal NANOPULSE-AF IDE study for drug-resistant paroxysmal atrial fibrillation, ...

The appointment gives a former Abbott leader oversight of efforts to bring a pulsed field ablation device to market.

RESET-PSVT is intended to generate prospective evidence to inform the real-world use of recently approved CARDAMYST and demonstrate its potential impact on the acute management of PSVT. Results are ...

U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary ...

Pulse Biosciences is keeping the noise level up by announcing the enrollment of the first patients in the NANOPULSE-AF study, ...

From its first use in 1998, to its status as a routine management strategy when medication is not an option, our understanding of catheter ablation for AF has grown immensely 4. Over the past 28 years ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation ...

On Wednesday, March 25, members and guests of the Pattaya City Expats Club were treated to a practical, case-driven lesson in heart rhythm disorders as “Doc” Martyn Green used a real consultation to ...

Heart conditions are pretty serious on their own—there’s no doubt about that. You may experience scary symptoms such as chest pain, shortness of breath, dizziness, swelling and palpitations, for ...